M. Mahlke

Is first-line single-agent mitoxantrone in the treatment ofhigh-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial

E. Heidemann, Herbert Stoeger, Rainer Souchon et al. · Annals of Oncology · 2002 · 49 citations

Breast Oncology, Oncology, Combination Chemotherapy +9

p53 expression and resistance against paclitaxel in patients with metastatic breast cancer

M Schmidt, A. Bachhuber, Anja Victor et al. · Journal of Cancer Research and Clinical Oncology · 2003 · 45 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +9

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer

Marcus Schmidt, E. Bremer, Dirk Hasenclever et al. · British Journal of Cancer · 2007 · 26 citations · Full text

Oral High-Dose Medroxyprogesterone Acetate (MPA) Treatment: Cortisol/MPA Serum Profiles in Relation to Breast Cancer Regression

M. Mahlke, H.‐J. Grill, P. Knapstein et al. · Oncology · 1985 · 20 citations

Medroxyprogesterone Acetate, Cortisol Serum Levels, Oncology +14